RGA study highlights potential of incretin-based therapies to improve global health outcomes
Reinsurance News - Nov 13, 2025
Reinsurance Group of America, Incorporated, a provider of life and health reinsurance solutions, has released new research that evaluates the potential effects of incretin-based therapies, including GLP-1 medications, on mortality and morbidity. These drugs, used for both weight management and diabe...
Recommended Articles
Posted: Dec 24, 2025
After several years of outperformance, European reinsurers’ momentum has stalled, with analysts warn...
Posted: Dec 24, 2025
Lee Gammon has been promoted to the newly created position of Head of Marine & Aviation of AXIS...
Posted: Dec 24, 2025
Globe Life Inc., a US-domiciled holding company specialising in life and supplemental health insuran...